GlassScriptPhysician profile
Nathan S White
NPI 1134106024
$5,948.68
in general payments reported to CMS, 2019-2025
27 companies · $4,744 in 2025
The $4,744 reported for 2025 was more than what 97% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2022: $202 · 2023: $310 · 2024: $384 · 2025: $4,744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,100 · Food and Beverage: $1,476 · Travel and Lodging: $863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,099.99 |
| Food and Beverage | $1,475.62 |
| Travel and Lodging | $863.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,012.03 | 2025 | |
| Astellas Pharma US INC | $287.78 | 2023-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $268.82 | 2019-2025 | Liletta |
| Biogen, INC. | $172.52 | 2025 | Zurzuvae |
| Lupin INC. | $121.24 | 2019 | |
| Sage Therapeutics, LLC | $119.97 | 2022-2025 | Zurzuvae |
| Coopersurgical, INC. | $119.13 | 2023-2025 | Paragard T 380a, Endosee, Paragard T 380a |
| Mayne Pharma Commercial LLC | $113.06 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $85.21 | 2025 | Myfembree |
| Exact Sciences Corporation | $79.31 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $78.94 | 2022-2024 | Aptima, Novasure |
| Organon LLC | $75.40 | 2023-2025 | Nexplanon |
| Therapeuticsmd, INC. | $61.28 | 2019-2022 | |
| Vertical Pharmaceuticals, LLC | $47.44 | 2019 | |
| Aspira Women'S Health INC | $45.21 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $42.55 | 2022-2023 | Injectafer |
| Merck Sharp & Dohme LLC | $36.87 | 2019-2024 | Gardasil 9, Gardasil |
| Shield Therapeutics INC | $30.12 | 2023 | Accrufer |
| Meditrina | $23.64 | 2025 | |
| Evofem Biosciences, INC. | $21.20 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.63 | 2024 | |
| Millicent US INC | $16.40 | 2024 | Intrarosa, Femring |
| Amgen INC. | $16.03 | 2019 | |
| Ibsa Pharma INC. | $15.84 | 2025 | Tirosint, Flector, Licart |
| Exeltis, USA INC. | $15.76 | 2022 | |
| Horizon Therapeutics Plc | $13.71 | 2023 | Tepezza |
| Acessa Health INC. | $10.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.